Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial.
Al-Shahi Salman R, Minks DP, Mitra D, Rodrigues MA, Bhatnagar P, du Plessis JC, Joshi Y, Dennis MS, Murray GD, Newby DE, Sandercock PAG, Sprigg N, Stephen J, Sudlow CLM, Werring DJ, Whiteley WN, Wardlaw JM, White PM; RESTART Collaboration.
Al-Shahi Salman R, et al.
Lancet Neurol. 2019 Jul;18(7):643-652. doi: 10.1016/S1474-4422(19)30184-X. Epub 2019 May 22.
Lancet Neurol. 2019.
PMID: 31129065
Free PMC article.
Clinical Trial.
There were no clinically or statistically significant hazards of antiplatelet therapy on recurrent intracerebral haemorrhage in primary subgroup analyses of cerebral microbleed presence (2 or more) versus absence (0 or 1) (adjusted hazard ratio [HR] 0.30 [95% CI 0.08-1.13] vs 0.7 …
There were no clinically or statistically significant hazards of antiplatelet therapy on recurrent intracerebral haemorrhage in primary subg …